C3 glomerulopathies. A new perspective on glomerular diseases

Nefrologia

Volumn 33, Issue 2, 2013, Pages 164-170

  Rabasco Ruiz, Cristina ^a   Huerta Arroyo, Ana ^a   Caro Espada, Jara ^a   Gutiérrez Martínez, Eduardo ^a   Praga Terente, Manuel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Alternative pathway of complement; C3 Glomerulonephritis; C3 Glomerulopathy; Dense deposit disease

Indexed keywords

COMPLEMENT COMPONENT C3;

CLASSIFICATION; HUMAN; IMMUNOLOGY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PROGNOSIS; SHORT SURVEY;

COMPLEMENT C3; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; PROGNOSIS;

EID: 84875840919     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Nov.11802     Document Type: Short Survey

References (28)

1. Bomback A, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012;8:634-42.
2. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005;16:1392-403.
3. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010;6:494-9.
4. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011;31:341-8.
5. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:729-40.
6. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-A new look at an old entity. N Engl J Med 2012;366:1119-31.
7. Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits:a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9.
8. D'Agati VD, Bomback AS. C3 glomerulopathy:what's in a name? Kidney international 2012;83:379-81.
9. Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int 2009;75:1230-4.
10. Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 2011;6:1009-17.
11. West CD, Witte D, McAdams A. Composition of nephritic factor generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 2001;37:1120-30.
12. Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376:794-801.
13. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702-12.
14. Shahidi-Asl M, Ananth M, Boieneau F, Meleg-Smith S. Apparent progression of acute glomerulonephritis to dense deposit disease. Ultrastruct Pathol 2000;24:273.
15. Meleg-Smith S. The many faces of C3 glomerulopathy. Kidney Int 2012;82:611.
16. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play acritical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64.
17. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 Glomerulonephritis: clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and followup. Kidney Int 2012;82:465-73.
18. Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012;7:265-74.
19. Schmidt CQ, Slingsby FC, Richards A, Barlow PN. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011;76:254-63.
20. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012;81:434-41.
21. Zuber J, Fakhouri F, Roumenina L, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-57.
22. Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of densedeposit disease. N Engl J Med 2012;366:1163-5.
23. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012;366:1161-3.
24. Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012;366:1165-6.
25. McCaughan J A, O'Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012;12:1046-51.
26. Bomback AS, Smith R, Barile G, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748-56.
27. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, et al.; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704.
28. Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, et al.; Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Long-Term Outcomes of IgA Nephropathy Presenting with Minimal or No Proteinuria. J Am Soc Nephrol 2012;23:1753-60.